GlassScriptPhysician profile
Kamal J Patel
NPI 1386748408
$3,347.82
in general payments reported to CMS, 2019-2025
32 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $370 · 2021: $651 · 2022: $882 · 2023: $90.16 · 2024: $87.40 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $527.45 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $436.86 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $239.70 | 2020-2021 | |
| Abbvie INC. | $208.51 | 2021-2024 | |
| Lilly USA, LLC | $198.66 | 2019-2022 | |
| Radius Health, INC. | $144.17 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $132.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.72 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $117.53 | 2019-2020 | |
| Amgen INC. | $116.02 | 2019-2022 | |
| Allergan, INC. | $102.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $88.38 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $82.76 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $71.80 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $64.84 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.79 | 2019-2021 | |
| Glaxosmithkline, LLC. | $61.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.21 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $44.08 | 2022-2023 | Nuedexta |
| Genentech USA, INC. | $42.69 | 2019-2021 | |
| Bausch Health US, LLC | $35.93 | 2021 | |
| Lucid Diagnostics INC. | $26.65 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.63 | 2022 | |
| Eisai INC. | $19.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.56 | 2019 | |
| Abbott Laboratories | $16.19 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.98 | 2020 | |
| Boston Scientific Corporation | $13.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.